Sify.com » Topics » Generics
Generics News
Pharma: In the pink of health
Pharma companies may put up a strong set of numbers due to robust domestic growth and the global generics opportunity. The BSE Healthcare index has underperformed the Sensex by about nine percentage points in the September quarter, which is not surprising. As the risk appetite increases among investors, the pharma sector, which is a defensive play, will not do as well as the broader market. However,
Pharma companies may put up a strong set of numbers due to robust domestic growth and the global generics opportunity. The BSE Healthcare index has underperformed the Sensex by about nine percentage points in the September quarter, which is not surprising. As the risk appetite increases among investors, the pharma sector, which is a defensive play, will not do as well as the broader market. However,
Drug seizure dispute with India not resolved: EU
The European Commission clarified today that no breakthrough in the ongoing dispute between India and the European Union (EU) regarding generic drug seizures had been reached. In response to
Drug patent row: seizure issue with EU resolved
India’s position accepted, patent rules to be amended to plug loopholes.
India’s position accepted, patent rules to be amended to plug loopholes.
Performance-enhancing drugs for your portfolio
Rising share in the US generics market and off-patent opportunities should benefit top Indian drug makers.
Rising share in the US generics market and off-patent opportunities should benefit top Indian drug makers.
Eli Lilly loses patent case to generics majors
Generic drugmakers, including domestic companies like Sun Pharmaceutical and Aurobindo will gain, as Eli Lilly has lost a US court case over its hyperactivity disorder drug, Strattera.
Generic drugmakers, including domestic companies like Sun Pharmaceutical and Aurobindo will gain, as Eli Lilly has lost a US court case over its hyperactivity disorder drug, Strattera.
Momenta receives OK for generic version of Lovenox
Biotechnology company Momenta Pharmaceuticals Inc. says the U.S. Food and Drug Administration has approved its generic version of the Sanofi-Aventis SA injected blood thinner Lovenox.
Biotechnology company Momenta Pharmaceuticals Inc. says the U.S. Food and Drug Administration has approved its generic version of the Sanofi-Aventis SA injected blood thinner Lovenox.
© Copyright Sify Technologies Ltd, 1998-2011. All rights reserved. India News Portal, Sify.com hosted at SifyHosting India's first Level 3 Internet Data Centre.
Site optimized for Internet Explorer 5.5 and above.
See Disclaimer |Privacy Policy &Parental Guidance on pornography |careers@sify |About Us |Feedback |Advertise
Site optimized for Internet Explorer 5.5 and above.
See Disclaimer |Privacy Policy &Parental Guidance on pornography |careers@sify |About Us |Feedback |Advertise